Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®

Skin Aging Clinical Trial

— DermiAge  

Official title:

Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05813054
• Other study ID #: PJ-00106
• Status: Recruiting
• Phase: N/A
• Start date: October 1, 2022
• Est. completion date: May 5, 2023

Study information

• Verified date: March 2023
• Source: Bioiberica
• Contact: PATRICIA GALVEZ
• Phone: 619515110
• Email: pgalvez[@]bioiberica.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Oral supplement with an HA matrix ingredient composed of HA (60-75%), sulfated GAGs (≥10%), including DS and CS, and collagen (≥ 5%) to evaluate the hydration of the stratum corneum of facial skin in healthy women showing natural signs of age-related aging versus placebo

Description:

This study includes 60 healthy volunteers in which will be evaluated if the oral supplement with Dermial [composed of HA (60-75%), sulfated GAGs (≥10%), including DS and CS, and collagen (≥ 5%)] is able to obtain differences versus placebo in healthy women showing natural signs of age-related aging versus placebo . It is a single-center, double-blind, randomized, placebo-controlled clinical study with proportion 1:1 between treatments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: May 5, 2023
• Est. primary completion date: May 5, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy women between 35 and 65 years of age (inclusive), showing signs of physiological facial skin aging.

2. Women willing not to use any firming product, skin lightening, or any other topical or systemic medication known to affect skin aging or dyschromia during the study period.

3. Be informed of the nature of the study and give their IC in writing.

4. Women willing not to become pregnant during the course of the study, using contraceptive methods considered highly effective.

Exclusion Criteria:

1. Women with allergies to the ingredients in the investigational product.

2. Women who have used a dietary or nutricosmetic supplement containing HA, or who have undergone Botox or HA infiltrations, in the last 6 months prior to signing the IC.

3. Women who have undergone:

• Superficial or medium-deep chemical peels or dermabrasion within the 6 weeks prior to signing the IC or inclusion document.

• Deep facial chemical peel, non-ablative laser or fractional laser resurfacing in the 12 months prior to signing the IC or inclusion document.

• Facial plastic surgery or a laser ablative procedure for photoaging in the 12 months prior to signing the IC or inclusion document.

4. Suspected uncontrolled disease, such as diabetes mellitus (DM), arterial hypertension (HT), hyperthyroidism or hypothyroidism, renal failure or liver failure.

5. Women who have received a PRP (Platelet Rich Plasma) injection as a treatment for aesthetic purposes, in the 3 months prior to inclusion by signing the IC.

6. Women who do not wish, for whatever reason, to take the supplements in the study.

7. Known pregnancy or lactation.

8. Presence of inflammatory skin disease such as psoriasis, atopic dermatitis, rosacea, acne or hidradenitis suppurativa.

9. Presence of active malignant pathologies or premalignant skin lesions such as actinic keratoses.

10. Psychiatric disorder that is not managed or any other circumstance or pathology that prevents the participant from understanding and/or complying with the study procedures.

Related Conditions & MeSH terms

• Skin Aging

Intervention

Dietary Supplement:
• HA matrix ingredient
1 capsule/day
• Placebo
1 capsule/day

Locations

Country	Name	City	State
Spain	Hospital Virgen de las Nieves	Granada

Sponsors (1)

Lead Sponsor	Collaborator
Bioiberica

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Skin Moisture	The changes in the hydration of the facial stratum corneum using the Corneometer® CM825 measuring device, range: 0-130 arbitrary units	Day 0, 12 week
Secondary	Skin Moisture	Evaluate changes in the hydration of the facial stratum corneum from baseline to 6 and 12 week by Corneometer® CM825 measuring device, range: 0-130 arbitrary units	Day 0, 6 week, 12 week
Secondary	Skin elasticity	The changes of skin elasticity by Cutometer ® Dual MPA 580 probe, range: 0-100%.	Day 0, 6 week, 12 week
Secondary	Skin hardness	The changes of Skin hardness by PCE-DDO 10 Durometer probe, range: 0-100 Shore O.	Day 0, 6 week, 12 week
Secondary	Skin Barrier	The changes of skin barrier in terms of TEWL (Trans Epidermal Water Loss) by Tewameter® TM300 probe, range: 0-80 (g*m-2*h-1).	Day 0, 6 week, 12 week
Secondary	Skin pH	The changes of skin pH by Skin-pH-Meter®PH905 probe, range: pH0 (acidic) - pH12 (alkaline).	Day 0, 6 week, 12 week
Secondary	Skin temperature	The changes of the skin temperature by Skin-Thermometer ST500 probe, range: 15°C-40°C.	Day 0, 6 week, 12 week
Secondary	Antioxidant capacity of the skin	The total antioxidant capacity will be measured in microcoulombs, using conductive hydrogel strips designed for the direct measurement of antioxidant capacity using eBQC®, range: 0-20 microcoulombs.	Day 0, 6 week, 12 week
Secondary	Erythema and skin melanin index	The erythema and melanin index will be measured in arbitrary units using the Mexameter® MX18 probe, range: 50-600 arbitrary units .	Day 0, 6 week, 12 week
Secondary	Skin stiffness/deformability	The changes of the stiffness/deformability by Indentometer IDM 800 probe, range: 0.00-3.00 millimeters.	Day 0, 6 week, 12 week
Secondary	Skin friction	The changes of the skin friction by Frictiometer FR-700, range: 0-30 arbitrary units .	Day 0, 6 week, 12 week
Secondary	Skin radiance	The changes of the skin radiance by Skin-Glossymeter GL 200 probe, range: 0-100 arbitrary units.	Day 0, 6 week, 12 week
Secondary	Facial Wrinkles and Fine lines of Crow's feet	Assessment of Reduction in Facial Wrinkles and Fine lines of Crow's feet area by VisioScan. It consists of a UV light camera and measures the skin surface profiles. (0-500 Rz)	Day 0, 6 week, 12 week
Secondary	Glogau Photodamage Scale	The change between the photodamage grade by dermatologist physical examination of treated area. The Glogau Photodamage Scale has a score from 1-4 (Type I: No wrinkles, Type II: Wrinkles in motion, Type III: Wrinkles at rest, Type IV: Only wrinkles), this scale represents a qualitative assessment to measure the severity of photodamage and wrinkles.	Day 0, 6 week, 12 week
Secondary	Satisfaction assessed	Level of satisfaction with the sensation of skin hydration, texture, luminosity and smoothness using a self-administered 5-point Likert scale of intensity ( 1_Very dissatisfied; 2_Dissatisfied; 3_Neither satisfied nor dissatisfied; 4_Satisfied; 5_Very) satisfied	Day 0, 12 week
Secondary	Safety assessment	Adverse events	Day 0 to 12 week (anytime)